Abstract: The invention relates to a pressing system, including a press having a first pressing tool and a second pressing tool. The first pressing tool and the second pressing tool being movable relative to one another to form a working space. A workpiece, a pressure generating device for generating a pressure curve acting on the workpiece in the working space, a temperature generating device for generating a temperature curve acting on the workpiece in the working space the workpiece running through an elongation curve (DVW) depending on the pressure curve acting in the working space and on the temperature curve acting in the working space. The first pressing tool and the second pressing tool running through a respective elongation curve (DVP1, DVP2) depending on the pressure curve acting in the working space and on the temperature curve acting in the working space, wherein the first pressing tool and/or the second pressing tool are designed such that their elongation curve (DVP1, DVP2) deviates by no more than 3.

Abstract: A cast iron material and methods for using same are disclosed, as well as a method for producing and/or lining a mould. The cast iron material has a change in length at temperatures of ?60° C. to 440° C., more particularly in the temperature range from 0° C. to 420° C., which change in length is as small as possible or as similar as possible to that of carbon fibre reinforced polymer or glass-fibre reinforced plastic. The cast iron material has at least the following proportions in percent by weight as elements or as compounds of carbon in the range from approximately 1.5% to 4.0%, silicon in the range from approximately 1.0% to 5.0%, manganese in the range from approximately 0.1% to 1.5%, nickel in the range from approximately 36.5% to 48.0%, chrome in the range from approximately 0.01 to 0.25%, phosphorus to approximately 0.08%, copper to approximately 0.5%, magnesium to approximately 0.150%, the remainder being iron and unavoidable impurities.

Abstract: A system for analyzing and interpreting at least one data stream comprises at least two extraction modules and at least one aggregation module that is configured to receive tagged data fragments from the at least two extraction modules. The aggregation module is configured to combine the tagged data fragments received from the at least two extraction modules to one session data. Further, a method of combining data fragments is described.

Abstract: An apparatus for identifying network devices comprises a data acquisition unit that receives data from a multiplicity of network devices. It also comprises an interpretation unit that extracts identification data from the data and determines which of the multiplicity of network devices has sent the received data. A similarity of measured data of a physical clock to a predefined pattern and/or to previously measured data of the physical clock is analysed as a first criterion of an association of received data. In addition, at least one further criterion of an association of received data can be analysed among the identification data.

Abstract: A system for analyzing and interpreting at least one data stream comprises at least two extraction modules and at least one aggregation module that is configured to receive tagged data fragments from the at least two extraction modules. The aggregation module is configured to combine the tagged data fragments received from the at least two extraction modules to one session data. Further, a method of combining data fragments is described.

Abstract: The present invention relates to co-crystals of ibrutinib and a pharmaceutical composition comprising the same as well as a method of preparing the same.

Abstract: The present invention relates to an adduct of palbociclib, a method of preparing the preparing the same, and a pharmaceutical composition comprising the same. More particularly, the invention provides a crystalline form of palbociclib, a method of preparing the same, as well as a pharmaceutical composition comprising the same.

Abstract: The present invention relates to co-crystals of ibrutinib, a pharmaceutical composition comprising the same as well as a method of preparing the same.

Abstract: The present invention relates to co-crystals of ibrutinib and a pharmaceutical composition comprising the same as well as a method of preparing the same.

Abstract: An apparatus for identifying network devices comprises a data acquisition unit that receives data from a multiplicity of network devices. It also comprises an interpretation unit that extracts identification data from the data and determines which of the multiplicity of network devices has sent the received data. A similarity of measured data of a physical clock to a predefined pattern and/or to previously measured data of the physical clock is analysed as a first criterion of an association of received data. In addition, at least one further criterion of an association of received data can be analysed among the identification data.

Abstract: The present invention relates to calcium salts of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in crystalline form and to a process for producing calcium salts of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in crystalline form. Further, the present invention relates to a composition comprising a crystalline calcium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid and to a dosage form containing the composition of the invention.

Abstract: The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.

Abstract: The present invention relates to an adduct of palbociclib, a method of preparing the same, as well as a pharmaceutical composition comprising the same.

Abstract: The present invention relates to co-crystals of ibrutinib, a pharmaceutical composition comprising the same as well as a method of preparing the same.

Abstract: The present invention relates to a composition comprising cebranopadol in dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising cebranopadol in dissolved form and to the corresponding process of producing an oral dosageform containing the composition of the invention.

Abstract: The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Sofosbuvir and pharmaceutical compositions thereof.

Abstract: The present invention relates to a composition comprising tapentadol in a dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising tapentadol in a dissolved form and to the corresponding process of producing an oral dosage form containing the composition of the invention. Finally, the invention relates to the use of a saturated tapentadol solution for the preparation of a solid oral dosage form.

Abstract: The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition.

Abstract: The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition.